The United Kingdom and the United States have hammered out a significant trade agreement that will ensure no duties on British medicine products being sold in the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase spending on medicines through the NHS. This commitment secures that duties on these crucial goods will remain at nothing for a timeframe of 36 months.
This agreement is in response to earlier threats to dramatically increase duties on patented pharmaceutical imports, with increases floated as high as 100%.
"This arrangement between the UK bolsters the global environment for new treatments and brings long-overdue equity to American-British pharmaceutical trade," an announcement declared.
Economic Significance
Drugs are one of the Britain's largest exports to the US, which is easily the largest destination for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months leading up to September, the UK shipped drugs valued at over eleven billion pounds to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This deal secures employment, stimulates investment and facilitates the UK to become a worldwide center for biotech and pharma," a government official stated.
Detailed UK Commitments
The agreement involves several specific changes from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to raise total health service expenditure on treatments from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The amount drug companies must pay back to the NHS to control costs will be limited at 15%. Last year, refunds were more than 20%.
Broader Context
The pact takes place against a protracted dispute between the sector and the ministers over medicine costs and NHS adoption.
These tensions were intensified by arguments that American patients were charged a premium for the same drugs than people in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been pledged toward American operations.
One official publicly accepted that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a share of its overall budget over the last ten years.
